(Q48368209)

11 February 2018

title

Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. (English)

1 reference

11 February 2018

0 references

1 reference

6

1 reference

11 February 2018

Klaus Müller

3

object named as

Klaus Müller

1 reference

11 February 2018

author name string

Johannes Rieger

1

1 reference

11 February 2018

Oliver Bähr

2

1 reference

11 February 2018

Kea Franz

4

1 reference

11 February 2018

Joachim Steinbach

5

1 reference

11 February 2018

publication date

25 December 2009

1 reference

11 February 2018

Journal of Neuro-Oncology

published in

1 reference

11 February 2018

volume

99

1 reference

11 February 2018

issue

1

1 reference

11 February 2018

page(s)

49-56

1 reference

11 February 2018

https://scigraph.springernature.com/pub.10.1007/s11060-009-0098-8

exact match

0 references

cites work

High-grade glioma before and after treatment with radiation and Avastin: initial observations

1 reference

12 December 2020

Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment

1 reference

12 December 2020

Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.

1 reference

12 December 2020

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

12 December 2020

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

1 reference

12 December 2020

High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis

1 reference

12 December 2020

Quantitative apparent diffusion coefficients in the characterization of brain tumors and associated peritumoral edema.

1 reference

12 December 2020

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan

1 reference

12 December 2020

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

1 reference

12 December 2020

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

1 reference

12 December 2020

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

12 December 2020

Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions.

1 reference

12 December 2020

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

1 reference

12 December 2020

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

1 reference

12 December 2020

Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.

1 reference

12 December 2020

Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice

1 reference

12 December 2020

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 reference

12 December 2020

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

1 reference

12 December 2020

Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.

1 reference

12 December 2020

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma

1 reference

12 December 2020

Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms

1 reference

12 December 2020

Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness

1 reference

12 December 2020

Apparent diffusion coefficients in the evaluation of high-grade cerebral gliomas

1 reference

12 December 2020

10.1007/S11060-009-0098-8

Identifiers

DOI

1 reference

11 February 2018

1 reference

11 February 2018